Arkstone, a leader in AI/ML for infectious disease decision support and antimicrobial stewardship, has been acquired by ARCHIMED, a prominent healthcare-focused private equity firm.
This acquisition is a key step in Arkstone’s growth, allowing it to expand globally and enhance its research and development efforts. Supported by ARCHIMED’s resources and expertise, Arkstone aims to strengthen its fight against antimicrobial resistance (AMR), a significant public health challenge.
Arkstone’s OneChoice Report uses ML and AI to provide tailored treatment recommendations for infectious diseases by analyzing lab results alongside patient data. This innovative tool is already transforming healthcare practices in the U.S. and internationally.
Following the acquisition, Arkstone will continue with its existing team, focusing on rapid growth, product development, and market expansion. This partnership emphasizes the significance of antimicrobial stewardship, positioning Arkstone as a leader in AI-driven infectious disease management.
KEY QUOTES:
“Arkstone’s OneChoice Report is redefining infectious disease management. Our partnership will enable Arkstone to reach more markets, accelerate product innovation, and ultimately save lives by reducing the misuse of antibiotics. This deal offers an additional dimension, as Clinical Decision Support software (CDS) and infectious disease are at the crossroads of hot subsectors of our Healthcare IT and Diagnostics franchises.”
Igor Petricca, Partner at ARCHIMED
“ARCHIMED’s acquisition of Arkstone supercharges our mission and opens new horizons for innovation and global reach. This partnership ensures we have the resources, network, and strategic guidance to deliver our vision globally. Together, we’ll expand access to the tools clinicians need to combat antimicrobial resistance and prescribe responsibly.”
Ari Frenkel, MD, MPH, Chief Science Officer and Co-Founder of Arkstone
“This partnership marks a transformative milestone for Arkstone. ARCHIMED’s deep expertise and global presence will significantly enhance our ability to innovate rapidly and bring life-saving antimicrobial stewardship solutions to a broader global audience. We’re thrilled to begin this exciting new chapter.”
Dave Gross, Chief Technology Officer and Co-Founder of Arkstone
“This acquisition is a powerful affirmation of the deep trust we’ve earned with our partners and the world-class support our team delivers. This is an opportunity to bring our personalized approach to even more partners, innovate faster, and deepen the collaborative relationships that have always defined Arkstone’s success.”
Sol Levi, Chief Customer Officer and Co-Founder at Arkstone
